Nuvilex to Present at the Third Annual Marcum MicroCap Conference
May 28 2014 - 2:00PM
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage international
biotechnology company providing cell and gene therapy solutions for
the treatment of diseases, announced today that its CEO and
President, Kenneth L. Waggoner, will be a featured presenter at the
Third Annual Marcum MicroCap Conference on Thursday, May 29, 2014
in New York City at the Grand Hyatt Hotel. The Company's
presentation by Mr. Waggoner is scheduled to begin at 3:30 p.m.
EDT.
The annual Marcum MicroCap Conference is a signature showcase
for superior quality, under-followed public companies with less
than $500 million in market capitalization. For more information or
to register, visit the conference website at
http://www.marcumllp.com/microcap or download the free official
conference app for the iPhone and iPad or for Android mobile
devices in Apple's App Store and the Google Play Market.
About Nuvilex Nuvilex (OTCQB:NVLX) is a
clinical stage biotechnology company focused on developing and
patented technology preparing to commercialize treatments for
cancer and diabetes based upon a proprietary cellulose-based
live-cell encapsulation technology known as Cell-in-a-Box®. This
unique and will be used as a platform upon which treatments for
several types of cancer, including advanced inoperable pancreatic
cancer, and diabetes are being built. Nuvilex's treatment for
pancreatic cancer involves the widely used anticancer prodrug
ifosfamide, together with encapsulated live cells, which convert
ifosfamide into its active or "cancer-killing" form. Nuvilex is
also working towards clinical trials associated with the symptoms
of advanced pancreatic cancer and other abdominal cancers.
About Marcum
Marcum LLP is one of the largest independent public accounting
and advisory services firms in the United States. Ranked #15
nationally, Marcum LLP offers the resources of 1,300 professionals,
including over 160 partners in 23 offices throughout the U.S.,
Grand Cayman and China. Headquartered in New York City, Marcum's
presence runs deep, with full-service offices strategically located
in major business markets. Marcum is a member of the Marcum Group,
an organization providing a comprehensive range of professional
services spanning accounting and advisory, technology solutions,
wealth management and executive and professional recruiting. The
Marcum Group companies include Marcum LLP; Marcum Technology LLC;
Marcum Search LLC; Marcum Financial Services LLC; Marcum Bernstein
& Pinchuk LLP; MarcumBuchanan Associates LLC; and Marcum Cronus
Partners LLC. For more information, visit www.marcumllp.com.
Safe Harbor
This press release may contain forward-looking statements
regarding Nuvilex and its future events and results that involve
inherent risks and uncertainties. The words "anticipate,"
"believe," "estimate," "expect," "intend," "plan" and similar
expressions, as they relate to Nuvilex or its management, are
intended to identify forward-looking statements. Important factors,
many of which are beyond the control of Nuvilex, that could cause
actual results to differ materially from those set forth in the
forward-looking statements include Nuvilex's ability to continue as
a going concern, delays in clinical trials or flaws or defects
regarding its products, changes in relevant legislation or
regulatory requirements, uncertainty of protection of Nuvilex's
intellectual property and Nuvilex's continued ability to raise
capital. Nuvilex does not assume any obligation to update any of
these forward-looking statements.
More information about Nuvilex can be found at www.nuvilex.com.
It can also be obtained by contacting Investor Relations
Contacts.
CONTACT: Investor Relations Contacts:
Marlin Molinaro
Marmel Communications, LLC
Phone: 702.434.8692
mmolinarofc@aol.com
Dillon Heins
CorProminence, LLC
Phone: 218.839.9051
dillonh@corprominence.com